Literature DB >> 12769605

Mutational analysis of the serotonergic system: recent findings using knockout mice.

Jay A Gingrich1.   

Abstract

Serotonin modulates numerous processes in the central nervous system related to anxiety and fear, mood, aggression, sleep, ingestive behaviors, reward systems, and psychosis. Serotonergic dysfunction has been implicated in several neuropsychiatric conditions but efforts to develop more specific pharmacological agents have been hampered by the complexity of this system at the receptor level. There are at least 14 distinct receptors that mediate the effects of serotonin as well as several enzymes that control its synthesis and metabolism but very few pharmacological agents are able to selectively target a single receptor. Several groups including ours have used a genetic strategy to ablate specific serotonin receptors in an effort to dissect out their functions in the central nervous system. The strength of this approach is the high degree of specificity that can be achieved in the knockout (gene inactivation) approach since a single receptor gene can be selectively targeted. To date several inactivation mutations of specific serotonin receptors have been generated producing interesting behavioral phenotypes related to anxiety, depression, drug abuse, psychosis, and cognition. In many cases knockout mice have been able to confirm what has already been suspected based on pharmacological studies. In other instances, mutations have demonstrated new functions of serotonergic genes in development and behavior. In this review, the current literature regarding phenotypic changes in mice bearing inactivation mutations of serotonin receptors, the serotonin transporter, and the monoamine oxidase A will be discussed and major findings emphasized.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12769605     DOI: 10.2174/1568007023339003

Source DB:  PubMed          Journal:  Curr Drug Targets CNS Neurol Disord        ISSN: 1568-007X


  8 in total

1.  High social support buffers the effects of 5-HTTLPR genotypes within social anxiety disorder.

Authors:  Eva Reinelt; Maren Aldinger; Malte Stopsack; Christian Schwahn; Ulrich John; Sebastian E Baumeister; Hans Jörgen Grabe; Sven Barnow
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-01-10       Impact factor: 5.270

Review 2.  Sleep disturbances in Alzheimer's and Parkinson's diseases.

Authors:  Sarah M Rothman; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2012-05-03       Impact factor: 3.843

Review 3.  Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.

Authors:  Moussa B H Youdim; Y S Bakhle
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

4.  Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation.

Authors:  Abigail Polter; Sufen Yang; Anna A Zmijewska; Thomas van Groen; Ji-Hye Paik; Ronald A Depinho; Stanford L Peng; Richard S Jope; Xiaohua Li
Journal:  Biol Psychiatry       Date:  2008-09-27       Impact factor: 13.382

5.  Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study.

Authors:  Tomohiro Kobayashi; Etsuko Hayashi; Midori Shimamura; Mine Kinoshita; Niall P Murphy
Journal:  Psychopharmacology (Berl)       Date:  2008-02-15       Impact factor: 4.530

Review 6.  The serotonergic system and anxiety.

Authors:  Joshua A Gordon; Rene Hen
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

7.  The psychobiology of resilience and vulnerability to anxiety disorders: implications for prevention and treatment.

Authors:  Dennis S Charney
Journal:  Dialogues Clin Neurosci       Date:  2003-09       Impact factor: 5.986

8.  Behavioral alterations in response to fear-provoking stimuli and tranylcypromine induced by perinatal exposure to bisphenol A and nonylphenol in male rats.

Authors:  Takayuki Negishi; Katsuyoshi Kawasaki; Shingo Suzaki; Haruna Maeda; Yoshiyuki Ishii; Shigeru Kyuwa; Yoichiro Kuroda; Yasuhiro Yoshikawa
Journal:  Environ Health Perspect       Date:  2004-08       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.